DK1429807T3 - Kombination af et NSAID og en PDE4-inhibitor - Google Patents

Kombination af et NSAID og en PDE4-inhibitor

Info

Publication number
DK1429807T3
DK1429807T3 DK02772313T DK02772313T DK1429807T3 DK 1429807 T3 DK1429807 T3 DK 1429807T3 DK 02772313 T DK02772313 T DK 02772313T DK 02772313 T DK02772313 T DK 02772313T DK 1429807 T3 DK1429807 T3 DK 1429807T3
Authority
DK
Denmark
Prior art keywords
combination
nsaid
pde4 inhibitor
derivative
inhibitor
Prior art date
Application number
DK02772313T
Other languages
Danish (da)
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of DK1429807T3 publication Critical patent/DK1429807T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02772313T 2001-09-19 2002-09-17 Kombination af et NSAID og en PDE4-inhibitor DK1429807T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number Publication Date
DK1429807T3 true DK1429807T3 (da) 2007-06-18

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02772313T DK1429807T3 (da) 2001-09-19 2002-09-17 Kombination af et NSAID og en PDE4-inhibitor

Country Status (25)

Country Link
US (2) US20040242597A1 (de)
EP (1) EP1429807B1 (de)
JP (1) JP4588998B2 (de)
KR (1) KR100949528B1 (de)
CN (1) CN100496607C (de)
AT (1) ATE355080T1 (de)
AU (1) AU2002337105B2 (de)
BR (1) BR0212606A (de)
CA (1) CA2459757C (de)
CY (1) CY1108011T1 (de)
DE (1) DE60218497T2 (de)
DK (1) DK1429807T3 (de)
EA (1) EA008108B1 (de)
ES (1) ES2282469T3 (de)
HK (1) HK1066730A1 (de)
HU (1) HU229442B1 (de)
IL (2) IL160271A0 (de)
MX (1) MXPA04002562A (de)
NO (1) NO331756B1 (de)
NZ (1) NZ532278A (de)
PL (1) PL210463B1 (de)
PT (1) PT1429807E (de)
SI (1) SI1429807T1 (de)
WO (1) WO2003024489A2 (de)
ZA (1) ZA200402654B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
BRPI0415753A (pt) * 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
EP1683521A1 (de) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptid-Deformylase-Inhibitoren, deren Verwendung und pharmazeutische Zusammensetzungen, welche sie enthalten
EP1688413A1 (de) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazolderivate zur Prophylaxe und Behandlung von entzündlichen Darmerkrankungen
US20080171746A1 (en) * 2005-03-14 2008-07-17 Thomas Klein Method for Preventing Cardiovascular Diseases
EP1898894A1 (de) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp-iv-hemmer zur behandlung von atemwegserkrankungen
PL2012763T3 (pl) * 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
JP5406215B2 (ja) 2008-01-25 2014-02-05 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー TNF−α合成の調節因子及びPDE4阻害剤としての三環系化合物
BRPI0908276B8 (pt) * 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
US9161927B2 (en) 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753597A1 (en) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
US20230017266A1 (en) * 2019-12-03 2023-01-19 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2023009352A (es) 2021-02-10 2023-08-16 Iolyx Therapeutics Inc Metodos para la administracion oftalmica de roflumilast.
JP2024534570A (ja) * 2021-09-22 2024-09-20 イオリクス セラピューティクス,インコーポレーテッド 眼炎症性疾患を処置する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
JP2001521926A (ja) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
AU5873000A (en) 1999-06-24 2001-01-31 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
DE60043318D1 (de) * 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7354941B2 (en) * 2000-01-31 2008-04-08 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
HUP0300689A3 (en) * 2000-02-08 2003-09-29 Smithkline Beecham Corp Method and compositions for treating an inflammatory disease
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
KR20030074817A (ko) * 2001-02-15 2003-09-19 알타나 파마 아게 Pde4 억제제로서의 프탈라지논-피페리디노-유도체

Also Published As

Publication number Publication date
NO331756B1 (no) 2012-03-19
MXPA04002562A (es) 2004-05-31
JP2005504077A (ja) 2005-02-10
EA200400410A1 (ru) 2004-12-30
CN1625411A (zh) 2005-06-08
US20080255209A1 (en) 2008-10-16
KR20040053129A (ko) 2004-06-23
DE60218497T2 (de) 2007-11-08
EA008108B1 (ru) 2007-04-27
SI1429807T1 (sl) 2007-08-31
PT1429807E (pt) 2007-05-31
NO20041596L (no) 2004-06-18
PL210463B1 (pl) 2012-01-31
IL160271A (en) 2008-03-20
US20040242597A1 (en) 2004-12-02
CN100496607C (zh) 2009-06-10
ATE355080T1 (de) 2006-03-15
ZA200402654B (en) 2005-04-26
AU2002337105B2 (en) 2008-03-20
WO2003024489A2 (en) 2003-03-27
BR0212606A (pt) 2004-08-17
DE60218497D1 (de) 2007-04-12
JP4588998B2 (ja) 2010-12-01
KR100949528B1 (ko) 2010-03-25
EP1429807B1 (de) 2007-02-28
EP1429807A2 (de) 2004-06-23
CY1108011T1 (el) 2013-09-04
WO2003024489A3 (en) 2003-09-18
HUP0401582A3 (en) 2008-04-28
HUP0401582A2 (hu) 2004-11-29
CA2459757C (en) 2011-08-30
HU229442B1 (hu) 2013-12-30
ES2282469T3 (es) 2007-10-16
IL160271A0 (en) 2004-07-25
US8242146B2 (en) 2012-08-14
NZ532278A (en) 2006-02-24
HK1066730A1 (en) 2005-04-01
PL369472A1 (en) 2005-04-18
CA2459757A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
DK1429807T3 (da) Kombination af et NSAID og en PDE4-inhibitor
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
CY1105586T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με θειοαιθερα
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
IS2457B (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DK2287156T3 (da) 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
DK2014304T3 (da) Kolonrensende sammensætninger
DK2090575T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af N4 phenylquinazolin-4-aminderivater
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60218012D1 (de) Optischer Verstärker
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
DK1871380T3 (da) Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
SE0102808D0 (sv) New compounds
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
EA200602082A1 (ru) Производные индол-2-она для лечения расстройств центральной нервной системы, желудочно-кишечных расстройств и сердечно-сосудистых расстройств
MY141010A (en) Use of ppar agonists for the treatment of congestive heart failure
ITMI20022738A1 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4.